News

Australian Good Design Awards

Posted: 14 September 2023 The Australian Good Design Awards Ceremony is the ultimate showcase of creativity, innovation and design mastery, bringing together the biggest names in the design world to celebrate the year’s best. With a black-tie atmosphere,…

Rhythm Biosciences Contracts with Nutripath on Automation Agreement

Posted: 14 September 2023 As per 31 July (Appendix 4C), transformative cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (“Rhythm” or the “Company”) is pleased to confirm it has progressed the Company’s objective to automate the ColoSTAT®…

geneType Granted Approval for Pancreatic Cancer, Melanoma, and Atrial Fibrillation in Australia

Posted: 11 September 2023 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that the expanded geneType Multi-Risk Test is now available…

New Fund Synthesis Capital to power Australia and the Asia-Pacific’s health ventures

Posted: 11 September 2023 A new pathbreaking fund to drive the growth of Australia’s medtech and deeptech health ventures is now raising. Launched this week at the 10-year celebration of the MedTech Actuator’s pathbreaking Origin program, Synthesis Capital…

BioMedTech Horizons Program

Posted: 11 September 2023 Delivered by MTPConnect, the Australian Government’s $45 million BioMedTech Horizons program (BMTH), is a Medical Research Future Fund (MRFF) initiative to support innovative collaborative health technologies, drive discoveries towards proof-of-concept and commercialisation that address key…

Neo-Bionica Launches Hermitization Capability at Melbourne Manufacturing Headquarters

Posted: 6 September 2023 Neo-Bionica, an advanced MedTech contract manufacturer based in Melbourne, is pleased to announce the expansion of its manufacturing services with the launch of its new hermitization capability. This marks the first time that Australian…

Changes to VivaZome’s Executive and Board

Posted: 5 September 2023 VivaZome Therapeutics Pty Ltd (“VivaZome” or “Company”) is pleased to announce a suite of changes to its Executive and Board. Ms Xenia Sango has been promoted to the position of CEO and Managing Director…

New discovery: dual acting drug delivers blood cancer a lethal ‘one-two’ punch

Posted: 4 September 2023 Melbourne researchers have designed a single drug that delivers a lethal ‘one-two’ punch to several types of blood cancer in preclinical studies and could lead to improved treatments. The collaboration between medicinal chemists, laboratory and clinician scientists at…

New insights on why epilepsy develops, potential treatments in world’s largest genetic study  

Posted: 4 September 2023 Specific changes in our DNA that increase the risk of developing epilepsy have been discovered, in the largest genetic study of its kind for epilepsy coordinated by the International League Against Epilepsy, which includes…

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

Posted: 4 September 2023 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations from its bioMUSE natural history study of Multiple…

Approval & first order for Xprecia Prime in India

Posted: 4 September 2023 Universal Biosensors, Inc. (ASX: UBI) is pleased to announce it has received approval from the Indian Central Drugs Standard Control Organisation (CDSCO) for the sale of Xprecia Prime, with the first order received from…

ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Program of INNA-051 in Community-Acquired Viral Respiratory Infections

Posted: 4 September 2023 Clinical-stage pharmaceutical company ENA Respiratory has been awarded an additional $3.8 million contract from the U.S. Department of Defence (DOD) to support ongoing research and development of INNA-051, a first-in-class, intranasal, innate immune modulator…

Home

News & opinion

Member Directory

Events